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tions of proBNP (pg/ml) in those with HF and LVD were 269 and 117, respectively and 
were significantly higher than normals (20pg/ml), p<O.OOl. The AUC on ROC analysis for 
the diagnosis of HF in the cohort was 0.85. In a multiple logistic regression analysis the 
independent predictors of HF (Odds Ratios) were IHD (3.9), a log unit increase in 
proBNP (2X), diabetes (2.2), hypertension (2) and increasing age (1.4). Our cut-point for 
“an abnormal proBNP” rssjlted in a sensitivity of 75%, specificity of 79% and a negative 
predictive value of 99% for detecting HF. In this population an abnormal pro-BNP value 
was explained by a significant cardiac structural, functional or renal problem in 89% of 
cases. Restricting our analysis to subjects with dyspnoea, we could explain 95% of high 
proBNP values on the basis of cardiac or renal dysfunctron. We had 22 ‘false negative” 
dyspnoeic subjects. Of these 16 (72%) were on cardiovascular medication which could 
reduce proBNP levels. 
Conclusions:This large pooled population analysis conflrms the usefulness of pro-BNP 
in diagnosing heart failure and has demonstrated what “hyperBNPaemia” is due to when 
cut-points based on abnormality are applied. 
1013-81 Tailoring Beta-Blocker Therapy in Patients With Chronic 
Heart Failure Utilizing NT-Pro-BNP 
Nicola Johnston, Mary Green, Stephen Robb, Ian Morton, Henry Dargie, Western 
Infirmary, Glasgow, United Kingdom 
Studies have provided evidence that beta-blockers (BE) decrease mortality in patients 
with chronic heart failure (CHF). However, surveys carried indicate the use of BB in clini- 
cal practice is still low (between 9% and 52%). This is partly due to difficulties III imple- 
mentation of BB and reluctance to commence BB in the community. The aim of this study 
was to examine implementation of BB in a heart failure clinic and to assess the use of 
NT-pro BNP to predict toleration of BB therapy. 
115 consecutive patients referred to the CHF clinrc for commencement of BB were 
included. Data collected detailed aetiology of CHF, co-morbidity and concurrent drug 
therapy, as well as LV function from the initial echocardiogram. At visit 1 the lowest 
licensed dose of 88 was started and doubled every 2 weeks until maximum dose was 
achieved. Patients were observed for 2 hours each visit, and pulse and blood pressure 
were recorded every 30 minutes. Physical examination was carried out at each atten- 
dance assessing weight, JVP, peripheral oedema and chest signs of pulmonary oedema. 
Side-effect profile was recorded, as well as follow-up data on drug compliance. NT-pro 
BNP was measured at initial visit and on average every 3 months thereafter. Average 
age was 67 (range 19-88 years of age). Of the patients referred 48.7% had severe LVD. 
45.0% moderate LVD and 6.3% mild LVD. 89.5% patients tolerated BB therapy with 
41.9% established on full dose therapy. Average time taken to establish the patient on 
their maximum tolerated dose was 10 weeks (range 8-44 weeks). Multivariate analysis 
was performed using Cox regression analysis. The only significant, independent, predic- 
tors of toleration of BB therapy were NT-pro BNP level before commencement of BB and 
during uptitration of BB. The higher the NT-pro BNP level, the less likely the patient was 
to tolerate BB therapy. A history of COPD or PVD did not predict toleration of BB and nor 
did NYHA class or severe LVD. 
BB therapy can be effectively commenced in the majority of patients with CHF. NT-pro 
BNP predicts which patients will tolerate BB therapy and could be of use to determine 
which patients could safely be commenced and uptitrated on BB in the community rather 
than attending hospital supervised programroes. 
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1014-59 B-Type Natriuretic Peptide Levels in Patients With 
Hypertrophic Obstructive Cardiomyopathy Treated With 
Alcohol Septal Ablation 
SteDhen M. Tans Christopher Nielsen, Donna Killip, David S. Feldman, William H 
Spencer, Ill, Medical University of South Carolina, Charleston, SC 
Background: In patients with cardiomyopathy, the serum B-type natiuretic peptide 
(BNP) level has been used as a biochemical marker for assessing the degree of heart 
failure decompensation. and as a long-term prognostic indicator. BNP has been shown 
to be elevated in both systolic and diastokc heart failure. Patients with hypertrophic 
obstructive cardiomyopathy (HOCM) exhibit symptoms of decompensated heart failure 
based on left ventricular outflow tract (LVOT) obstruction and diastolic dysfunction. The 
purposes of this study were to determine if BNP levels are elevated in patients with 
symptomatic HOCM, and if these levels would decrease with successful alcohol septal 
ablation. Methods: Serum BNP levels were drawn in 10 consecutive patients at base- 
line, 24 and 48 hours. Peak LVOT gradients at rest and with Valsalva were measured by 
echo Doppler pre and post procedure. Results: See table below: 
Pre-Ablation 24 hours post ablation 48 hours post ablation 
BNP (peg/ml) 578 +I- 155 193 +I- 55 172 +/- 22 
LVOT rest (mmHg) 70.6 +I- 7.4 14.8 +I- 1.8 
LVOT valsalva (mmHg) 104.3 +/- 8.4 40 +/- 5.7 
After alcohol septal ablation, serum BNP levels decreased by 67% at 24 hours 
(p=O.O24), and 71% at 48 hours (p=O.O14). The resting LVOT gradient decreased by 
79% (p<O.OOOl) after the procedure, and with Valsalva the LVOT gradient decreased by 
62% (p<O.OOOl). Conclusions Serum BNP levels are elevated in patients with elevated 
peak LVOT gradients and symptomatic HOCM. Successful treatment with alcohol septal 
ablation produced a marked decrease in peak LVOT gradient and serum BNP levels. 
BNP levels may be considered as a surrogate marker for therapeutic success after alco- 
hol septal ablation. 
1014-60 Echo-Guided Septal Ablation for Hypertrophic 
Obstructive Cardiomyopathy: Six.Years of Experience 
Lothar Faber, Dirk Welge, Hubert Seggewiss, Dieter Fassbender, Ulrich Glerchmann. 
Dieter Horstkotte, Heart Center North Rhine-Westphalia, Bad Oeynhausen, Germany, 
Leopoldma Hospital, Schweinfurt. Germany 
Background: Ethanol-induced septal ablation for symptomatic hypertrophic obstructive 
cardiomyopathy (HOCM) requires the exact definition of the septal myocardium to be 
abladed. We report on our cumulative experience with PTSMA guided by intra-proce- 
dual contrast echo (MCE) on an intention-to-treat basis in 322 patients (pts.) treated 
from 1 /1996 - 12/2001. 
Aesuks: Ethanol could not be infected I” 26 pts. (8%), predominantly due to an 
unwanted extension of the target region as documented by MCE in 18 pts. (6%). In 33 
out of the 296 pts. pts. (11%) who received ethanol, a target vessel (TV) change was 
necessary for the same reason. In-hospital mortality was 1.4% (4 pts.). After 3 months, 
symptoms had improved in 262 pts. (69%) from NYHA class 2.8r0.5 to 1.520.6, with a 
mean increase in exercise capacity by 21+46 watts (p<O.OOOl each). 157 pts. (53%) 
reported to be free of symptoms. A satisfactory mid-term (3 months) reduction of the left 
ventricular outflow gradient (LVOTG) was achieved in 243 pts. (82%; from 56+33 to 
13+18 Hg at rest and 119*44 to 37-35 mm Hg with provocation; pcO.0001). 119 pts. 
(43%) were free from outflow obstruction. LVOTG with probatory balloon occlusion dur- 
ing the intervention was 39+31 mm Hg (p<O.OOi). There was a weak correlation between 
the LVOTG with probatory balloon occlusion (PBO) and the residual LVOTG after 3 
months (0.3; pcO.001). PBO-induced LVOTG reduction was >30% in 159 pts. (54%) and 
>50% in only 112 pts. (38%). 
Conclusions: In case of a positive intra-procedural MCE study, PBO adds llttle informa- 
tion with respect to lV selection in PTSMA for HOCM. Furthermore, MCE is able to 
exclude alcohol necrotization of myocardium remote from the septal target area, and 
thus adds to the safety of the procedure. 
1014-61 Insulin-Like Growth Factor-l Attenuates Myocardial 
Hypertrophic Response to Sarcomeric Mutations in 
Human Familial Hypertrophic Cardiomyopathy 
David A. Bealey, Said1 A. Mohiddin. Andrew E. Arai, Jing-Ping Lin, Dorothy Tripodi, 
Lameh Fananapazir, National Institutes of Health, Bethesda, MD 
Background: Familial hypertrophic cardiomyopathy (FHC) is caused by mutations in sar- 
comeric contractile proteins. Impaired sarcomeric function leads to expression of a vari- 
ety of genes, resulting in compensatory left ventricular (LV) hypertrophy. The severity of 
the cardiac hypertrophy is an important determinant of clinical outcome. LV hypertrophy, 
is however, highly variable in affected family members with an idendical disease muta- 
tion. The reasons for the marked differences in phenotypic expressron are not known. 
Insulin-like growth factor-l (IGF-1) plays an important role in cardiomyocyte viability and 
function. We therefore hypothesized that variations in IGF-1 levels account for some of 
the phenotypic heterogeneity in FHC. Methods: Plasma IGF-1 and its binding protein 
IGFBPS, and LV indices measured by magnetic resonance imaging, were measured in 
100 subjects with diverse mutations causal for FHC (mean age, 30+2 years; 43 males), 
and 50 normal family members without disease mutation (controls). Results: IGF-1 levels 
increased between the ages of 5 and 20 years and decreased thereafter. IGF-1 levels 
were lower in FHC subjects but the decline with age in adults was similar to controls. In 
subjects with sarcomeric gene mutations, maximum LV wall thickness (LVWT) varied 
between 9 mm to 44 mm and correlated poorly with LV mass. There was a significant 
inverse correlation between IGF-1 levels (but not IGFBPB) and maximum LVWT in this 
subset (p=O.OOS), when age, gender, body surface area, IGFBP-3. and relation among 
family members in the study were controlled for. Notably, IGF-1 levels also correlated 
significantly with maximum LVWT:LV diastolic volume (p=O.O0026), a ratio which reflects 
LV wall stress. 
Conclusions: Elevated IGF-1 levels are protective and are associated with milder FHC 
phenotype, possibly because the increased IGF-I activity lessens myocyte contractile 
dysfunction induced by sarcomeric mutation, thereby attenuating the myocardial hyper- 
trophlc response. Our findings indicate that the use of octreotide to reduce IGF-1 levels 
in HCM, suggested by some workers, may have deleterious effects 
